Clairity raised $43 million to expand its AI mammography tool for predicting five-year breast cancer risk.
Key Details
- 1Clairity, founded in 2020 by Dr. Constance Lehman of Mass General, focuses on AI for breast cancer risk assessment.
- 2The company secured $43 million in Series B funding led by Ace Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation.
- 3Clairity Breast is the first AI tool to predict five-year breast cancer risk from standard mammograms.
- 4The product received FDA de novo authorization in May 2024.
- 5New funds will support commercialization and partnership expansion.
Why It Matters
Clairity's advancements could lead to earlier detection and prevention strategies using existing mammography infrastructure, potentially improving patient outcomes. The funding and FDA approval mark important milestones for AI adoption in radiology.
Source
Radiology Business
Related News
•Radiology Business
New AI Flags Uncertainty in Breast Cancer Imaging Predictions
University of Pittsburgh researchers developed an AI model that quantifies uncertainty in breast cancer diagnostic predictions to enhance trustworthiness.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.